Matches in Wikidata for { <http://www.wikidata.org/entity/Q37598258> ?p ?o ?g. }
- Q37598258 description "article científic" @default.
- Q37598258 description "article scientifique" @default.
- Q37598258 description "articolo scientifico" @default.
- Q37598258 description "artigo científico" @default.
- Q37598258 description "artículu científicu espublizáu en 2009" @default.
- Q37598258 description "bilimsel makale" @default.
- Q37598258 description "bài báo khoa học" @default.
- Q37598258 description "scientific article published on October 2009" @default.
- Q37598258 description "vedecký článok" @default.
- Q37598258 description "vetenskaplig artikel" @default.
- Q37598258 description "videnskabelig artikel" @default.
- Q37598258 description "vědecký článek" @default.
- Q37598258 description "wetenschappelijk artikel" @default.
- Q37598258 description "wissenschaftlicher Artikel" @default.
- Q37598258 description "наукова стаття, опублікована в жовтні 2009" @default.
- Q37598258 description "научни чланак" @default.
- Q37598258 description "مقالة علمية نشرت في أكتوبر 2009" @default.
- Q37598258 name "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 name "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 name "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 type Item @default.
- Q37598258 label "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 label "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 label "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 prefLabel "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 prefLabel "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 prefLabel "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 P1433 Q37598258-F09F9B6E-C453-46AD-AA48-12E2D4B34728 @default.
- Q37598258 P1476 Q37598258-E3E07EAE-ECD6-4221-8250-C6D187E70C8F @default.
- Q37598258 P2093 Q37598258-0B5AFA8B-A432-4EE5-843F-98C47DE10014 @default.
- Q37598258 P2093 Q37598258-0C6B05C8-A396-46DC-93B9-8EA9198A0B96 @default.
- Q37598258 P2093 Q37598258-2E609C3A-7276-4D32-87E8-C0239A916792 @default.
- Q37598258 P2093 Q37598258-4AFCF6B6-50FF-44E8-86A5-C3D7C2694741 @default.
- Q37598258 P2093 Q37598258-B7E35396-9A63-45D4-8439-0AE89FB9DCAD @default.
- Q37598258 P2860 Q37598258-03D232D2-B9D4-49F5-9935-3830ACA50323 @default.
- Q37598258 P2860 Q37598258-07C975F6-128F-4EE3-A0CF-02D9F773108E @default.
- Q37598258 P2860 Q37598258-0E5E4946-3A3F-40ED-AA2E-A813DB081A7F @default.
- Q37598258 P2860 Q37598258-198DF116-E2AA-4190-BAC9-210D540DD944 @default.
- Q37598258 P2860 Q37598258-22DC48FC-20C5-4EEC-84E1-ABE90AA405CD @default.
- Q37598258 P2860 Q37598258-2F036CC9-3EA5-4623-8209-85967CFA9C12 @default.
- Q37598258 P2860 Q37598258-304629D2-2EA1-47D7-8A46-3733822F88FE @default.
- Q37598258 P2860 Q37598258-3340F01D-9F20-4727-897F-01C823C171F5 @default.
- Q37598258 P2860 Q37598258-34E5606A-8D50-424A-99DE-9D5D11E4F907 @default.
- Q37598258 P2860 Q37598258-3E33E87A-5211-4CAB-8171-6B9E91B941F0 @default.
- Q37598258 P2860 Q37598258-3FE709FD-3A0E-478E-A123-D353FB8D53CE @default.
- Q37598258 P2860 Q37598258-48F2010F-592C-4306-B180-706344B0F853 @default.
- Q37598258 P2860 Q37598258-539D6D8A-D935-4C21-8DD6-CAC12AB6FACD @default.
- Q37598258 P2860 Q37598258-597F4E45-1059-43C4-8CE2-EB17747BDFFC @default.
- Q37598258 P2860 Q37598258-5ABCB8CC-697E-4E7C-997F-3950C39F5FF2 @default.
- Q37598258 P2860 Q37598258-6D2BB111-1F52-40C1-9DFC-853004C00DBE @default.
- Q37598258 P2860 Q37598258-701999CA-05EE-4357-893E-DB30AB8BF8A6 @default.
- Q37598258 P2860 Q37598258-75DAE31D-3155-4CA1-8CDC-A60B3F360CDD @default.
- Q37598258 P2860 Q37598258-76615241-DC4E-4FF5-A0A4-7360D05729ED @default.
- Q37598258 P2860 Q37598258-81A116CF-CE2F-4B08-ABDB-28870251F4AC @default.
- Q37598258 P2860 Q37598258-83B36C60-8581-40F8-A4BD-3631075460C2 @default.
- Q37598258 P2860 Q37598258-9A78F14C-6B29-44B2-B806-FD267A5FEEE9 @default.
- Q37598258 P2860 Q37598258-A44FF525-9B35-4C11-9D19-7F5694FB9E42 @default.
- Q37598258 P2860 Q37598258-AA33B1AF-E454-4D6A-A23B-7FE730B9C800 @default.
- Q37598258 P2860 Q37598258-AD6D04FA-8E97-4722-8E94-957C5C70E9AB @default.
- Q37598258 P2860 Q37598258-BA0D862B-AC97-4906-B979-5C2FA114B0E7 @default.
- Q37598258 P2860 Q37598258-BC897576-6D57-4DF1-B372-592978E6434F @default.
- Q37598258 P2860 Q37598258-C6512964-F080-43D8-9E50-9D97CCE27948 @default.
- Q37598258 P2860 Q37598258-DB4BA8AD-7ED5-4C37-9475-DDBFDE7BB418 @default.
- Q37598258 P2860 Q37598258-EF4B590D-0669-4CA0-BDCB-F0A525176E15 @default.
- Q37598258 P2860 Q37598258-F6F34324-2A80-4DDA-B5C2-2D8F3CC0DC8C @default.
- Q37598258 P2860 Q37598258-F7F2300C-0757-45F1-BF65-9326DD7A8C1B @default.
- Q37598258 P2860 Q37598258-FA60CCE5-949F-416D-AE6E-48086C17AA60 @default.
- Q37598258 P2860 Q37598258-FA6F892E-C22F-41FB-88E4-6ADC2D54EA8D @default.
- Q37598258 P2860 Q37598258-FAA1E69D-3D73-482F-8506-B4A11A73E8F7 @default.
- Q37598258 P304 Q37598258-BB7FF62C-249F-4B02-BF72-4ECBEDACDDB1 @default.
- Q37598258 P31 Q37598258-2bf2aced-65f6-4ac3-9c08-747961b829c9 @default.
- Q37598258 P31 Q37598258-A5298086-5813-49D6-BC3F-832AFC75D8AA @default.
- Q37598258 P356 Q37598258-7437E71F-3C9C-4B2E-A9F6-FA6EB6638184 @default.
- Q37598258 P407 Q37598258-420D3694-B3D6-4511-9CA1-85EFB8F7BF96 @default.
- Q37598258 P433 Q37598258-A41509A7-2757-4685-AA44-6025C9417FD8 @default.
- Q37598258 P478 Q37598258-4BE04DFE-828E-4A3E-9EDD-9FBCC152231D @default.
- Q37598258 P577 Q37598258-194AE3ED-C88F-42D4-A0B9-A6A655B85DE5 @default.
- Q37598258 P698 Q37598258-206E053C-EC58-443A-AC7E-07607D109F34 @default.
- Q37598258 P8608 Q37598258-6FDDA31E-6585-4FCE-845A-9B5A7EE6D6A5 @default.
- Q37598258 P921 Q37598258-05714E69-57CB-4663-81AD-854C84FDB127 @default.
- Q37598258 P921 Q37598258-11da53fc-918b-477e-bb2e-e39f7ca3e023 @default.
- Q37598258 P921 Q37598258-BEBFDF45-C397-47C4-B911-19AAD8AF5ACA @default.
- Q37598258 P356 14728220903241633 @default.
- Q37598258 P698 19758106 @default.
- Q37598258 P1433 Q5421208 @default.
- Q37598258 P1476 "Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors" @default.
- Q37598258 P2093 "Ali A Rizvi" @default.
- Q37598258 P2093 "Giatgen A Spinas" @default.
- Q37598258 P2093 "Giovam Battista Rini" @default.
- Q37598258 P2093 "Kaspar Berneis" @default.
- Q37598258 P2093 "Manfredi Rizzo" @default.
- Q37598258 P2860 Q22306384 @default.
- Q37598258 P2860 Q28578709 @default.
- Q37598258 P2860 Q34499706 @default.
- Q37598258 P2860 Q34598940 @default.
- Q37598258 P2860 Q34648377 @default.
- Q37598258 P2860 Q36861081 @default.
- Q37598258 P2860 Q37102964 @default.
- Q37598258 P2860 Q37160663 @default.
- Q37598258 P2860 Q37320190 @default.